Paladin Labs Inc, a leading Canadian specialty pharmaceutical company, has agreed to amendments to its existing agreements with Isotechnika Pharma Inc that will give Paladin the full share of future net profits of the Isodiagnostika line of diagnostic products in exchange for an undisclosed lump sum payable over the next twelve months.

"Our experience with the Isodiagnostika business over the last several months suggests that, in addition to providing an established base and capabilities from which to sell diagnostic products in Canada, the business, particularly the Helikit 13C-Urea Breath Test for helicobacter pylori, has untapped growth potential in Ontario and Quebec,” stated Jonathan Ross Goodman, president & CEO of Paladin Labs Inc. "The Helikit line of products holds further potential for export sales", Mr. Goodman also noted.

Helicobacter pylori bacteria (H. pylori) can infect the outer lining of the stomach, and has been conclusively linked to the development of the majority of duodenal and gastric ulcers, and is also associated with gastric cancer.

Paladin Labs is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets.